Multiple injections of human umbilical cord-derived mesenchymal stromal cells through the tail vein improve microcirculation and the microenvironment in a rat model of radiation myelopathy by unknown
Wei et al. Journal of Translational Medicine 2014, 12:246
http://www.translational-medicine.com/content/12/1/246RESEARCH Open AccessMultiple injections of human umbilical
cord-derived mesenchymal stromal cells through
the tail vein improve microcirculation and the
microenvironment in a rat model of radiation
myelopathy
Li Wei1,2*†, Jing Zhang1,6†, Xiu-Bin Xiao1†, Hai-Xing Mai1, Ke Zheng3, Wan-Liang Sun1,7, Lei Wang4, Feng Liang1,
Zai-Liang Yang5, Yuan Liu5, Yan-Qing Wang1, Zhi-Fang Li1, Jia-Ning Wang4, Wei-Jing Zhang1* and Hua You1*Abstract
Background: At present, no effective clinical treatment is available for the late effects of radiation myelopathy. The
aim of the present study was to assess the therapeutic effects of human umbilical cord-derived mesenchymal
stromal cells (UC-MSCs) in a rat model of radiation myelopathy.
Methods: An irradiated cervical spinal cord rat model was generated. UC-MSCs were injected through the tail vein
at 90, 97, 104 and 111 days post-irradiation. Behavioral tests were performed using the forelimb paralysis scoring
system, and histological damage was examined using Nissl staining. The microcirculation in the spinal cord
was assessed using von Willebrand factor (vWF) immunohistochemical analysis and laser-Doppler flowmetry.
The microenvironment in the spinal cord was determined by measuring the pro-inflammatory cytokines
interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in the serum and the anti-inflammatory cytokines
brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF) in the spinal cord.
Results: Multiple injections of UC-MSCs through the tail veil decreased the forelimb paralysis, decreased spinal
cord histological damage, increased the number of neurons in the anterior horn of the spinal cord, increased
the endothelial cell density and the microvessel density in the white matter and gray matter of the spinal
cord, increased the relative magnitude of spinal cord blood flow, down-regulated pro-inflammatory cytokine
expression in the serum, and increased anti-inflammatory cytokine expression in the spinal cord.
Conclusion: Multiple injections of UC-MSCs via the tail vein in a rat model of radiation myelopathy significantly
improved the microcirculation and microenvironment through therapeutic paracrine effects.
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The spinal cord is a well-known example of “late-react-
ing” tissue in response to irradiation [1]. Exposure of the
spinal cord to radiation can result in radiation myelopathy,
which is a rare but serious complication of radiotherapy
for cancer [2]. The late effects of radiation myelopathy
(i.e., those occurring 6 months to several years after treat-
ment) can be extremely severe and may seriously decrease
the patient’s quality of life. These effects are particularly
dangerous because they are generally irreversible [3,4].
Currently, there is no effective clinical treatment for the
late effects of radiation myelopathy.
Two distinct hypotheses—the glial hypothesis (demye-
lination) and the vascular hypothesis—have been devel-
oped to explain the underlying mechanisms leading to
the development of selective white matter necrosis and,
in particular, to identify the primary “target cell popula-
tion” within the CNS [4]. Vascular damage is considered
the key step in the development of radiation myelopathy
[1,2,4-8]. Hence, the vascular endothelial cell population
has been proposed as one of the most critical targets of
the late effects of radiation myelopathy [9].
Previous studies have examined early endothelial
cell apoptosis in the spinal cord after irradiation [10,11].
Radiation-induced apoptosis of endothelial cells has
been shown to depend on the ASMase pathway rather
than the p53 pathway [10]. Because we have clearly deter-
mined the time course of the endothelial cell response
within 180 days post-irradiation and demonstrated its
relationship with spinal cord blood flow [12], it seems
possible that targeting endothelial cell death may be a
neuroprotective strategy that can limit the late effects
of spinal cord irradiation [12,13].
Recently, multipotent mesenchymal stromal cell (MSC)
treatment has attracted special attention as a new alter-
native strategy for stimulating regeneration. MSCs are
primitive cells originating from the mesodermal germ
layer and are classically described as giving rise to con-
nective tissues, skeletal muscle cells, and cells of the
vascular system [14]. MSCs may exhibit immunosuppres-
sive properties and have been suggested to be “immune-
privileged”. They are thus protected from rejection,
potentially permitting their use in allo-transplantation.
It appears that MSCs have the capacity to localize to
injured tissue and differentiate into specific cell types
[15]. Some reports suggest that the therapeutic effects of
MSCs in injured tissue are mainly mediated by paracrine
activity, including the stimulation of endogenous repair,
angiogenesis and arteriogenesis; attenuation of remodel-
ing; and reduction of apoptosis [16]. Interestingly, injected
murine MSCs, but not human MSCs, differentiated
into osteosarcomas in injured lungs. Thus, human MSCs
appear to be more feasible and safer for use than murine
MSCs [17].The aim of the present study was to assess the thera-
peutic effects of human umbilical cord-derived mesen-
chymal stromal cells (UC-MSCs) in a rat model of
radiation myelopathy. To the best of our knowledge, this
is the first clinically based translational study to assess




Adult female Sprague–Dawley (SD) rats (160–200 g,
Laboratory Animal Center, Academy of Military Medical
Sciences, Beijing, China) were housed and cared for ac-
cording to the guidelines for the care and use of laboratory
animals of the NIH and Academy of Military Medical
Sciences (Beijing, China). All experimental procedures
were approved by the Committee for Animal Use at the
Academy of Military Medical Sciences. Every effort was
made to minimize the number of animals used as well as
their suffering. Water and food were available ad libitum
in the cages.
Isolation and differentiation of human UC-MSCs
UC-MSCs were isolated from Wharton’s jelly (WJ) of
umbilical cords according to previously described
methods with some modification [18]. Fresh umbilical
cords were collected after obtaining consent from the
mothers. The umbilical cords were rinsed in phosphate-
buffered saline (PBS) until the cord blood was cleared,
and the blood vessels were removed. The remaining WJ
tissue was cut into 1-2 mm3 pieces and placed in six-
well plates in the presence of 0.1% collagenase type II
(Sigma, USA) in PBS at 37°C for 1 h. Ten percent fetal
bovine serum (FBS, Invitrogen, USA) was then added to
stop the digestion. The dissociated mesenchymal cells
were dispersed in 10% FBS-DMEM and further cultured
until well-developed colonies of the fibroblast-like cells
reached 80% confluence. Then, the cultures were trypsi-
nized with 0.25% trypsin-EDTA (Invitrogen, USA) and
passaged into new flasks for further expansion. The
multipotent differentiation capacity of the UC-MSCs
was confirmed by their differentiation into adipocytes,
chondroblasts and osteoblasts using Oil Red O staining
(adipocytes), alcian blue staining (chondroblasts), and
alkaline phosphatase (osteoblasts), respectively. The sur-
face markers of the UC-MSCs were also examined by flow
cytometry.
Irradiation and UC-MSC injection
A total of 20 SD rats were randomly divided into 4 groups
(n = 5 each): normal control (control) group, untreated ir-
radiation (irradiation) group, PBS treatment (PBS) group,
and UC-MSC treatment (UC-MSC) group. Each rat in the
irradiation, PBS and UC- MSC groups was anesthetized
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by intraperitoneal injection and subsequently irradiated
using a 60Co source. A 60Co irradiator (Model GWXJ80,
NPIC, Chengdu, China) was used to conduct gamma ray
irradiation, and the rats were irradiated with 30 Gy at a
dose rate of approximately 150 cGy/min. The beam was
strictly limited to a 2-cm segment of the cervical spine
field spanning C2-T2. According to previous reports
[2,10,11,19], forelimb paralysis associated with white mat-
ter necrosis occurs approximately 20 weeks following the
delivery of single doses of 20 Gy or more to the cervical
spinal cord in this radiation myelopathy model. Single
doses of 19.5 and 22 Gy represent the ED50 and ED100,
respectively, for forelimb paralysis within 180 days sec-
ondary to white matter necrosis in the rat spinal cord
model. Rats in the PBS and UC-MSC groups were given
PBS and UC-MSC (1 × 106 cells) injections through the
tail vein in a 200 μl volume at 90, 97, 104 and 111 days
post-irradiation. Rats in the irradiation group were not
provided any treatment after irradiation. Rats in the con-
trol group were fed normally and not irradiated during
the same period. The rats were observed daily for up to
180 days post-irradiation.
Assessment of motor function
At 180 days post-irradiation, the motor function of five
rats was examined using a slightly modified version of
the methodology described by Chiang [20]. A technical as-
sistant who was blinded to the experimental conditions
evaluated the rats’ motor function. In the subjective scor-
ing system that was used, 0 represented total paralysis of
both forelimbs, 1 represented definite sub-total paralysis
(one forelimb paralyzed or slight movement of both fore-
limbs; toes do not spread when the animal is held up),
2 represented definite abnormal movement (very un-
steady movements, low stance, uncoordinated movements,
hops), 3 represented questionably abnormal movement
(slightly wobbly or uncoordinated movements), and 4 rep-
resented normal movement.
Assessment of spinal cord blood flow (SCBF)
SCBF was measured using a MoorLab laser-Doppler
flowmeter (MoorLab Instruments, Devon, England) as
described in our previous study [12]. This instrument re-
corded the relative change in blood flow over time.
Briefly, the animals were mounted on a stereotactic in-
strument equipped with a vertebral fixation device to
stabilize the vertebral column. Body temperature was
maintained at 37.0 ± 0.5°C using a heating blanket. The
laser-Doppler probe was affixed to a micromanipulator
and placed perpendicular to the spinal cord, barely touch-
ing the dorsal surface of the dura mater. Laser-Doppler
signal readings were recorded on a computer and were
analyzed using Moorsoft for Windows (version 1.31).SCBF was measured before irradiation (0 d) and 180 d
after irradiation. The mean value before irradiation (0 h)
was used as the basal value, and the final value for each
rat at each later time point was expressed as a percentage
of the basal value (100%).
Specimen processing and histology
After the SCBF assessment at 180 days post-irradiation,
blood samples were collected from the heart and allowed
to clot for 2 h at room temperature. Serum was obtained
after centrifugation at 2000 rpm for 20 min at 4°C and
stored at −80°C. The C2-T2 spinal cord segment was
removed, and a 1-cm-long central section of this seg-
ment was cut and immersed in 4% paraformaldehyde for
histological and immunohistochemical analysis. The
remaining portion of the spinal cord was frozen in dry
ice power and stored at −80°C prior to use. The previ-
ously mentioned 1-cm-long central section of the C2-T2
spinal cord segment was dehydrated in ethanol and em-
bedded in paraffin. The sections (5 μm thickness) were
deparaffinized, rehydrated, and stained using Nissl stain-
ing. For Nissl staining, the sections were incubated with
0.1% cresyl violet at 37°C for 10 min and subsequently
dehydrated, mounted, and observed under a light micro-
scope. Neurons with diameters > 20 μm in both anterior
horns of the spinal cord were counted.
Immunohistochemical analysis
The sections (5 μm thickness) were subjected to micro-
wave antigen retrieval using Tris-EDTA (pH 9, 10 min).
Endogenous peroxidase was quenched using 3% H2O2
for 10 min. The sections were incubated with polyclonal
rabbit anti-human von Willebrand factor (vWF, also
called factor VIII-related antigen) antibody (1:100 dilu-
tion; DakoCytomation, Denmark) or anti-human nuclei
antibody (MAB1281, 1:1000 dilution; Millipore) at 37°C
for 3 h. The primary antibody was omitted from the
negative control. After washing with PBS, the sections
were incubated with biotinylated monoclonal anti-rabbit
IgG for 20 min at room temperature using a SABC
Detection System (Boster Biological Technology, Wuhan,
China) according to the manufacturer’s protocol. The
slides were developed with diaminobenzidine (DAB;
DakoCytomation, Denmark), counterstained with Mayer’s
hematoxylin, dehydrated with increasing concentrations
of alcohol, cleared in xylene, and mounted in neutral bal-
sam (Sigma, USA).
ELISA
The levels of interleukin-1β (IL-1β) and tumor necrosis
factor-α (TNF-α) in the serum and the levels of brain-
derived neurotrophic factor (BDNF) and glial cell-
derived neurotrophic factor (GDNF) in the spinal cord
tissues were determined using commercially available
Wei et al. Journal of Translational Medicine 2014, 12:246 Page 4 of 12
http://www.translational-medicine.com/content/12/1/246ELISA kits according to the manufacturer’s protocols
(IL-1β and TNF-α, Invitrogen, Carlsbad, California,
USA; BDNF, MyBioSource, SanDiego, California, USA;
GDNF, Abnova, Taipei city, Taiwan). The OD value was
determined by an ELISA reader at a wavelength of
450 nm and calculated in the linear part of the curve.
Morphometric analysis
For the Nissl staining, two sections per rat were selected
in every sixth section, and a total of ten sections per
time point were carefully examined at 100X magnifica-
tion under an Olympus microscope [12]. According to
the methodology described previously by Li et al. and
our group [10-12], the endothelial cell density was defined
as the total number of endothelial cells that contained a
nucleus divided by the transverse cross-sectional area of
the spinal cord, and the microvessel density was defined
as the total number of microvessels that were transversely
sectioned and contained either an endothelial cell nucleus
or no nucleus divided by the transverse cross-sectional
area of the spinal cord. One hotspot area in the gray mat-
ter and another hotspot area in the white matter were
selected at 100X magnification. The densities of the
endothelial cells and microvessels were then determined
using two fixed fields (0.768 mm2) within each of these
two areas at 400X magnification per section. Three sec-
tions per rat were selected in every sixth section, and a
total of thirty fields per time point in the gray matter and
thirty fields per time point in the white matter were used
for the analysis. Image-ProPlus software was used for the
analyses. For morphometric analysis, two blinded patholo-
gists carefully and independently examined all selected
sections. The number of neurons, the endothelial cell
density and the microvessel density were determined in
the individual analyses, and mean values were calculated.
We used some data from our previous paper [12] as the
same experimental conditions which were employed in
the present work.
Statistics
All quantitative data are expressed as the mean value ±
SEM. Differences were evaluated using one-way ANOVA.
Comparisons between values at two time points were
performed using the least significant difference (LSD)




The UC-MSCs exhibited similar spindle- and fibroblast-
like shapes (Figure 1A). The multipotent differentiation
capacity of the UC-MSCs was confirmed by their differ-
entiation into adipocytes, osteoblasts and chondroblasts,
as shown by the staining of the in vitro differentiationcultures with Oil Red O (Figure 1B, adipocytes), alkaline
phosphatase (Figure 1C, osteoblasts), and alcian blue
(Figure 1D, chondroblasts). The surface markers of the
UC-MSCs were examined by flow cytometry. Most of
the cultured cells were positive for CD90, CD73 and
CD105 expression but negative for CD45, CD34, CD14,
CD19 and HLA-DR expression (Figure 1E-L).
UC-MSC administration improved locomotion recovery
To determine the potential benefit of the UC-MSC in-
fusion on the spinal cord after irradiation, behavioral
tests were performed using the forelimb paralysis scoring
system. Although we did not observe total paralysis at
180 days post-irradiation in our radiation myelopathy rat
model, in which demyelination did not occur, the irradi-
ated rats still exhibited significant forelimb motor func-
tion impairment compared with the normal controls
at 180 days post-irradiation [12]. In irradiated ani-
mals, UC-MSC treatment significantly decreased the
forelimb paralysis, compared with PBS treatment and no
treatment, indicating that irradiated animals treated with
UC-MSCs exhibited improved motor function (indicated
by a higher score on the test). There were no significant
differences in the forelimb paralysis score between PBS-
treated irradiated animals and untreated irradiated ani-
mals (Figure 2).
UC-MSC administration ameliorated irradiation-induced
histological damage in the spinal cord
Next, we evaluated whether UC-MSC injection could
decrease histological damage to the spinal cord after ir-
radiation. We previously determined that a single 30-Gy
dose of irradiation primarily injured the neurons in the
spinal cord. A markedly thickened cytoplasm, significant
swelling and distension of the soma, and hazy Nissl bod-
ies were observed in the neurons between 30 days and
90 days post-irradiation. After 90 days post-irradiation,
this neuronal damage was reversed to some degree [12].
Histological examination of spinal cord sections using
Nissl staining revealed neuronal damage similar to that
observed in the untreated irradiated animals and in the
PBS-treated animals at 180 days post-irradiation (Figure 3).
Interestingly, the neurons of UC-MSC-treated irradiated
animals were less damaged than those of untreated irradi-
ated animals (Figure 3).
We also counted the number of neurons in the anter-
ior horn of the spinal cord following irradiation using
Nissl staining. The number of neurons in the UC-MSC-
treated animals (15.6 ± 0.6) was significantly higher than
that in the PBS-treated animals (11.4 ± 1.0) and that in
the untreated irradiated animals (11.5 ± 1.8) at 180 days
post-irradiation (Figure 4). The number of neurons in
the PBS-treated animals was similar to that in the un-
treated irradiated animals (Figure 4).
A B C D 
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Figure 1 Culture and identification of UC-MSCs. (A) UC-MSCs exhibiteda spindle- and fibroblast-like shape. (B-D) Multipotential differentiation
of UC-MSCs. UC-MSC differentiation into adipocytes, osteoblasts and chondroblasts, as shown by Oil Red O (B), alkaline phosphatase (C), and
alcian blue (D) staining, respectively, of in vitro differentiation cultures. (E-L) Flow cytometry analysis of surface markers inUC-MSCs. Most of the
cultured cells were positive for expression of CD90 (E), CD73 (F) and CD105 (G) but were negative for expression of CD45 (H), CD34 (I), CD14 (J),
CD19 (K) and HLA-DR (L). The scale bar is 10 μm in A, 100 μm in B and C, and 50 μm in D.
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microcirculation dysfunction in the spinal cord
To explore angiogenesis induced by UC-MSC adminis-
tration, microvessels were identified with anti-factor VIII
antibody, a specific marker for endothelial cells. The endo-
thelial cell density and microvessel density were then
quantified in the white matter and gray matter of the
spinal cord (Figure 5). The endothelial cell and microves-
sel densities were significantly higher in the UC-MSC-
treated animals [endothelial cell density: (34.7 ± 2.8)/mm2
in the white matter, (115.9 ± 6.2)/mm2 in the gray matter;
microvessel density:(69.9 ± 4.6)/mm2in the white matter,
(255.2 ± 7.2)/mm2 in the gray matter] than those in the PBS-
treated animals [endothelial cell density: (25.2 ± 2.5)/mm2
in the white matter, (99.0 ± 4.6)/mm2 in the gray matter;
microvessel density: (56.0 ± 3.5)/mm2 in the white matter,
(237.4 ± 9.1)/mm2 in the gray matter] and those in the un-
treated irradiated animals [endothelial cell density (24.7 ±
3.0)/mm2 in the white matter, (99.0 ± 5.3)/mm2 in the graymatter; microvessel density (56.9 ± 4.5)/mm2 in the white
matter, (229.6 ± 9.6)/mm2 in the gray matter] at 180 days
post-irradiation (Figure 6). The endothelial cell and micro-
vessel densities were similar in the PBS-treated animals
and the untreated irradiated animals (Figure 6). We also
used a marker of human nuclei, MAB1281, to identify sur-
viving UC-MSCs in spinal cord sections by immunohisto-
chemistry. However, UC-MSCs were not found in spinal
cord sections of UC-MSC-treated animals (data not
shown).
To address the functional effects of alterations in
endothelialcell density and microvessel density, we ap-
plied laser-Doppler flowmetry to record the relative mag-
nitude of the spinal cord blood flow [12]. The relative
magnitude of the spinal cord blood flow in the UC-MSC-
treated animals (79.0 ± 4.3) was significantly higher than
that in the PBS-treated animals (64.8 ± 3.4) and untreated
irradiated animals (65.5 ± 3.1) 180 days post-irradiation

























Figure 3 UC-MSC administration decreased irradiation-induced histological damage in the spinal cord. Representative micrographs
of Nissl-stained rat spinal cords at 180 days post-irradiationfollowing systemic injection of UC-MSCs. Arrows indicate Nissl bodies.
Scale bars = 100 μm.




























Figure 4 UC-MSC administration improved neuron survival in the anterior horn at 180 days post-irradiation (n = 10, *P < 0.05, ▲P < 0.01).
Error bars represent the S.E.M.
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ated animals was similar (Figure 7).
UC-MSC administration reversed irradiation-induced
inflammation
We also determined whether the UC-MSC injection
could reverse the spinal cord inflammation that arises
after irradiation. We measured the levels of the pro-
inflammatory cytokines IL-1β and TNF-α in the serum






Figure 5 Representative micrographs of von Willebrand factor immun
of 30 Gy. Arrows,endothelial cells; arrowheads,microvessels. Scale bars = 20GDNF in the spinal cord tissues to assess the inflamma-
tory status. The irradiated rats exhibited significantly
higher levels of IL-1β (283.2 ± 14.7 pg/ml) and TNF-α
(118.2 ± 5.4 pg/ml) in the serum and lower levels of
BDNF (59.7 ± 4.9 pg/mg) and GDNF (65.4 ± 8.4 pg/mg)
in the spinal cord compared with the normal controls
[IL-1β: 221.2 ± 9.8 pg/ml; TNF-α: 92.8 ± 5.0 pg/ml;
BDNF:106.4 ± 14.1 pg/mg; GDNF:134.4 ± 13.6 pg/mg] at
180 days post-irradiation (Figure 8). The levels of IL-1β




















































































White Matter Gray Matter
Figure 6 UC-MSC administration increased the endothelial cell density (n = 30) and microvessel density (n = 30) in the spinal cord at
180 days post-irradiation (*P < 0.05, ▲P < 0.01). Error bars represent the S.E.M.
Wei et al. Journal of Translational Medicine 2014, 12:246 Page 8 of 12
http://www.translational-medicine.com/content/12/1/246serum of the UC-MSC-treated animals were significantly
lower than those in the PBS-treated animals [IL-1β: 273.8
± 13.6 pg/ml; TNF-α:117.6 ± 5.3 pg/ml] and those in the
untreated irradiated animals at 180 days post-irradiation
(Figure 8). The levels of BDNF (99.0 ± 17.8 pg/mg) and





















Figure 7 UC-MSC administration increased blood flow (n = 5) in the s
bars represent the S.E.M.UC-MSC-treated animals were significantly higher than
those in the PBS-treated animals [BDNF:60.1 ± 6.5 pg/mg;
GDNF: 74.4 ± 7.5 pg/mg] and those in the untreated irra-
diated animals at 180 days post-irradiation (Figure 8). The
levels of IL-1β and TNF-α in the serum and the levels of



































































































Figure 8 UC-MSC administration reversed irradiation-induced inflammation. Serum samples and spinal cord samples were collected from
animals at 180 days post-irradiation following systemic injection of UC-MSCs and analyzed by ELISA (*P < 0.05, ▲P < 0.01). Error bars represent
the S.E.M.
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animals (Figure 8).
Discussion
The primary aim of this work was to investigate the po-
tential beneficial effects of the delivery of UC-MSCs
through the tail vein on radiation myelopathy. In the
present study, using a rat model of radiation myelopathy,
we demonstrated that the administration of UC-MSCs
through the tail vein improved motor function, as shown
by decreased forelimb paralysis; decreased histological
damage in the spinal cord, as shown by Nissl staining of
spinal cord sections; increased the number of neurons in
the anterior horn of the spinal cord, as shown by Nissl
staining; increased endothelial cell density and the
microvessel density in the white matter and gray matter
of the spinal cord, as determined by vWF immunohisto-
chemistry; increased relative magnitude of spinal cord
blood flow, as measured by laser-Doppler flowmetry;
down-regulated pro-inflammatory cytokine expression
and increased anti-inflammatory cytokine expression, as
measured by an analysis of IL-1β and TNF-α levels in
the serum and BDNF and GDNF levels in the spinal
cord. Our data not only define the potential beneficial
roles of UC-MSC infusion through the tail vein but
also provide the first evidence that UC-MSCs haveparacrine therapeutic effects in a rat model of radiation
myelopathy.
The beneficial effects of cell-based therapies have been
demonstrated using different types of cells in pre-clinical
models. One of the most extensively studied cell types
used for traumatic spinal cord repair in experimental
models with good potential for clinical translation are
MSCs [21]. However, little is known about the mecha-
nisms underlying the potential benefits of cell grafting
into the injured spinal cord [22]. The beneficial effects
of MSCs have been attributed to several potential mecha-
nisms. MSCs produce neuroprotective molecules in injured
tissue [23,24], promote vascularization [24], modulate the
inflammatory response [22,25,26], and generate a permis-
sive microenvironment for axonal regeneration [27-29]. In
addition, MSCs have been shown to foster a positive rela-
tionship between the preservation of spinal cord paren-
chyma and functional and electrophysiological recovery
[23,24,27], and they were shown to promote axonal regen-
eration when transplanted after complete spinal cordtran-
section [29]. The therapeutic effects of immortalized neural
stem cells [2] and oligodendrocyte progenitor cells (OPCs)
[30] were previously determined in a rat model of radiation
myelopathy. The present study is the first to examine the
beneficial effects of MSCs in an animal model of radiation
myelopathy.
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factor that determines the beneficial effects of cell trans-
plantation for radiation myelopathy. We applied laser-
Doppler flowmetry to record the relative magnitude of
the spinal cord blood flow and discovered that the low-
est relative magnitude of spinal cord blood flow was
reached at 90 days post-irradiation [12]. Therefore, we
injected UC-MSCs at 90 days post-irradiation in our
rat model of radiation myelopathy, using spinal cord
blood flow as a reliable indicator of the optimal time for
transplantation.
The transplantation route has also been suggested to
be involved in the effectiveness of cell therapy [31]. For
clinical application, intravenous injection appears to be
the easiest method of delivering therapeutics to the pa-
tient without risking further damage to the spinal cord
[24]. Further, the efficacy and feasibility of delivering
MSCs by tail vein transfusion has been confirmed
[24,32,33]. In our initial study, we injected UC-MSCs
every 7 days through the tail vein and observed that the
rats died if they received an injection more than 5 times
(data not shown). Thus, we injected UC-MSCs through
the tail vein at 4 time points: 90, 97, 104 and 111 days
post-irradiation.
Compared to MSCs from other sources, the low im-
munogenicity and capacity for localized immunosup-
pression have been well documented for UC-MSCs [16].
UC-MSCs have been shown to survive, migrate over
short distances, produce large amounts of BDNF and
neurotrophin-3 (NT-3) in the host spinal cord, in-
duce fewer reactive astrocytes, increase the length of
neurofilament-positive fibers and the number of growth
cone-like structures around the lesion site, and enhance
hindlimb locomotor function [34]. Genetic modifica-
tion of UC-MSCs with NT-3 further enhanced their
therapeutic effectsafter clip injury to the spinal cord [35].
Injection of Schwann-like cells induced from UC-MSCs,
combined with NT-3 administration, further promoted
the survival of UC-MSCs and functional recovery [36]. A
combination treatment of Taxol and UC-MSCs for spinal
cord injury further reduced the extent of astrocyte activa-
tion, increased axonal preservation, decreased the number
of caspase-3(+) and ED-1(+) cells, and enhanced func-
tional recovery compared with UC-MSC treatment alone
[37]. Our results demonstrated that UC-MSC administra-
tion decreased irradiation-induced histological damage in
the spinal cord and ultimately improved locomotion re-
covery. These observations confirmed that the histological
improvement induced by MSCs could result in a higher
degree of functional recovery.
In the present study, UC-MSCs were not detected in
spinal cord sections from UC-MSC-treated animals based
on immunohistochemical staining of a marker of human
nuclei, MAB1281. We did not exclude the possibility thata very limited number of UC-MSCs still survived in the
radiation-injured spinal cord due to some limitations of
immunohistochemical technology. Reports from the early
period of MSC-based cell therapy for tissue repair demon-
strated that injected MSCs may survive, engraft, differenti-
ate into specific cell types, and repair injured tissues [15].
However, subsequent studies, including the present report,
supported the notion that the level of engraftment of
transplanted MSCs in the host organs of recipient animals
was very low. The exact mechanisms of MSC action in tis-
sue repair are poorly understood; however, the paracrine
action of MSCs has been highlighted in previous papers
[16]. Direct evidence for a paracrine role of MSCs has
been obtained and confirmed in studies utilizing animal
models of lung [38], heart [39], and liver [40] injury, which
showed that conditioned medium (CM) generated from
MSCs significantly reduced damage and stimulated re-
generation in vivo. Down regulation of pro-inflammatory
cytokines and up regulation of anti-inflammatory cyto-
kines have been proposed as paracrine effects of MSCs
[40]. Our results demonstrated that down regulation of
the pro-inflammatory cytokines IL-1β and TNF-α in the
serum occurred on a systemic level, and up regulation of
the anti-inflammatory cytokines BDNF and GDNF in the
spinal cord occurred on a local level. The controlled sys-
temic and local inflammatory responses may contribute to
endogenous regeneration mechanisms in the spinal cord.
MSCs have been demonstrated to increase the density
of new blood vessels in traumatized spinal cord tissue,
resulting in functional recovery [24,41]. We demonstrated
that UC-MSC injection increased the endothelial cell
density and the microvessel density in the white and gray
matter of the spinal cord and increased spinal cord blood
flow. This effect was induced by secreted factors that exert
paracrine effects on local endothelial cells [42].
Conclusions
In summary, we have demonstrated that multiple injec-
tions of UC-MSCs via the tail vein significantly improved
the microcirculation and microenvironment through para-
crine therapeutic effects in a rat model of radiation myel-
opathy. To the best of our knowledge, this is the first study
to evaluate MSC therapy for radiation myelopathy. The
present work may provide preclinical data for the treat-
ment of radiation myelopathy using human MSCs.
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